Summary Information:
Pulmonx Corporation Common Stock
NASDAQ:LUNG


email
admin@troach.net
Our Main Pages
Stocks.TRoach.Net
TRoach.Org
TRoach.Net

NOTE: This page is for evaluation of a JFF Project.
This page is NOT updated on a regular basis.
Information on this page should NOT be used for investment purposes.


Pulmonx Corporation Common Stock
Exchange: NASDAQ
Symbol: LUNG
SEC CIK: 0001127537
Phone: 650-364-0400
700 CHESAPEAKE DRIVE
REDWOOD CITY CA 94063

CEO:
Price when page updated: 11.16 Date: 2023-12-01
Company Website:
pulmonx.com

_Description: Pulmonx Corporation is a commercial-stage medical technology company. The Company is focused on providing planning tools and treatments for obstructive lung disease. Its solutions include Zephyr Valve, Chartis Pulmonary Assessment System and StratX Lung Analysis Platform. The Company's solutions offer minimally invasive treatment option for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). Its solution provides bronchoscopic lung volume reduction without surgery. The Zephyr Valves are indicated for bronchoscopic treatment of adult patients with hyperinflation associated with severe emphysema in regions of the lung that have little to no collateral ventilation. The Zephyr Valves are placed in the airways to occlude the diseased parts of the lung, allowing trapped air to escape.

IPO YEAR:
2020
Sector:
Health Care
Industry:
Industrial Specialties
ADRTSO:

MarketCap:
427518541.00
Beta:
1.917118039113575
52 Week High:
69.48
52 Week Low:
28.87
52 Week Change:
-0.4937135847899417
Short Interest:

Short Date:

Shares Outstanding:
36838698
Dividend Rate:
0
Dividend Yield:
N/A
ExDividend Date:

Latest EPS:

Latest EPS Date:
26 Oct 2022
Float:
0
return on Equity:
30.80%
Consensus EPS:

Number Of Estimates:

EPS Surprise Dollar:

Eps Surprise Percent:

EBITDA:
$197.278M
ttmEPS:
0
Revenue:
$1.128B
Gross Profit:

Cash:

Debt:

Institution Percent:
84.00%
Revenue Percent:

Revenue Per Employee:

Insider Percent:
2.20%
Return on Assets:
5.20%
Return on Capital:

Profit Margin:
24.80%
Price to Sales:
1.11
Price To Book:
1.08
Short Ratio:
4.01
PE Ratio:
0
Employees:
220
1Y Guesstimate
N/A:N/A:N/A




__The following are links to various summary and news pages for
__Pulmonx Corporation Common Stock [ LUNG ].

__Note: Some Links might not have information for the company.


finance.Yahoo.com money.CNN.com NASDAQ research
WalletInvestor.com WSJ.com MarketBeat.com
finviz.com WallMine.com TheGlobeandMail.com
stock1010.com
NASDAQ - General Info SEC Insider Report Ownership Summary
Dividend History insiderbuyingselling.com
Facebook search Twitter search LinkedIn search
PRnewsWire.Com Google Forecast
tdameritrade.com BarChart.com
SeekingAlpha.com Markets.FT.com stocktwits.com
FinTel.io Ldmicro.com bloomberg.com
MarketWatch.com Reuters.com businessinsider.com
fool.com barrons.com zacks.com
GuruFocus.com Investing.com tipranks.com
thestreet.com nytimes.com earningswhispers.com
marketchameleon.com sunshineavenue.com stockinvest.us
stockanalysis.com stockconsultant.com ycharts.com
financialcontent.com docoh.com foxbusiness.com
cnbc.com investorsobserver.com tradingview.com
investopedia.com tmxmoney.com invest.cnyes.com
ask.com bing.com brave.com
duckduckgo.com ecosia.org excite.com
exalead.com gibiru.com hotbot.com
www.info.com infospace.com lycos.com
lukol.com metacrawler.com mojeek.com
becovi.com searx.thegpm.org search.com
swisscows.com webcrawler.com yahoo.com
yandex.com yep.com you.com




INDEX




Page design by: TRoach
Page Last Updated: 2023-12-01